Generic Name and Formulations:
Halobetasol propionate 0.05%; crm; oint.
Sun Pharmaceutical Industries
Indications for ULTRAVATE:
Apply a thin layer to affected areas 1–2 times daily; max 50 g/week and 2 consecutive weeks' treatment per course. Discontinue when control is achieved. Do not occlude.
Avoid use near eyes, on face, groin, or axillae. Do not use for diaper dermatitis, rosacea, perioral dermatitis, or on pre-existing skin atrophy. Risk of HPA axis suppression with high-potency steroids, prolonged use, application to large surface area, use of occlusive dressings, altered skin barrier, liver failure, young age; discontinue gradually, or reduce dose or potency if occurs. Treat infection if present; discontinue if infection persists or worsens. Reevaluate periodically. Pregnancy (Cat.C). Nursing mothers.
Burning, stinging, itching, dry skin, erythema, skin atrophy, leukoderma, vesicles, rash, pustulation, acne, secondary infections, telangiectasia, urticaria, miliaria; HPA axis suppression (esp. in children).
Sign Up for Free e-newsletters
Psychiatry Advisor Articles
- Age of Onset of Bipolar Disorder Linked With Substance Use Disorders
- Mind-Body Therapy and Psychiatry: Ancient Tools for Modern Practice
- Marijuana Use Associated With Poorer Depression Outcomes, Increased Suicidal Ideation
- Short Forms of Parent General Behavior Inventory Reliable at Identifying Youth Mood Symptoms
- Low Testosterone Linked With Social Anxiety in Boys With Klinefelter Syndrome
- The Psychology of Hoarding Disorder: Approaches for Treatment
- Smartphone Applications for Depression and Anxiety: Are They Ready for Widespread Use?
- The Many Misconceptions of Catatonia: Treatment Is Often Successful With the Right Knowledge
- Digital Media Engagement Associated With ADHD Symptoms in Adolescents
- Strong Social Networks May Mitigate the Effects of Childhood Adversity
- Unexpected Effect of Substance Use Disorders on Recovery From Bipolar Depression
- Republican Opposition to Obamacare: What's Done, What's to Come
- Early Childhood Out-of-Home Placement Associated With Adverse Outcomes in Adulthood
- Opioid Use Disorder Prevalence at Delivery on the Rise in the US, According to CDC
- Integrating Treatments for Opioid Use Disorder and Infectious Diseases